The complement system is a key component of innate immunity, but impaired regulation influences disease susceptibility, including age-related macular degeneration and some kidney diseases. While complete complement inhibition has been used successfully to treat acute kidney disease, key unresolved challenges include strategies to modulate rather than completely inhibit the system and to deliver therapy potentially over decades. Elevating concentrations of complement factor I (CFI) restricts complement activation in vitro and this approach was extended in the current study to modulate complement activation in vivo. Sustained increases in CFI levels were achieved using an adeno-associated virus (AAV) vector to target the liver, inducing a 4- to 5-fold increase in circulating CFI levels. This led to decreased activity of the alternative pathway as demonstrated by a reduction in the rate of inactive C3b (iC3b) deposition and more rapid formation of C3 degradation products. In addition, vector application in a mouse model of systemic lupus erythematosus (NZBWF1), where tissue injury is, in part, complement dependent, resulted in reduced complement C3 and IgG renal deposition. Collectively, these data demonstrate that sustained elevation of CFI reduces complement activation in vivo providing proof-of-principle support for the therapeutic application of AAV gene delivery to modulate complement activation.
Get full access to this article
View all access options for this article.
References
1.
MorganBP, HarrisLC. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov, 2015; 14:857–877.
2.
LachmannPJ. Looking back on the alternative complement pathway. Immunobiology, 2018; 223:519–523.
3.
LachmannPJ. The amplification loop of the complement pathways. Adv Immunol, 2009; 104:115–149.
4.
BottoM, KirschfinkM, MacorP, et al.Complement in human diseases: lessons from complement deficiencies. Mol Immunol, 2009; 46:2774–2783.
HarrisCL, HeurichM, CordobaSRD, et al.The complotype: dictating risk for inflammation and infection. Trends Immunol, 2012; 33:513–521.
8.
HagemanGS, AndersonDH, JohnsonLV, et al.A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A, 2005; 102:7227–7232.
9.
PickeringMC, De JorgeEG, Martinez-BarricarteR, et al.Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med, 2007; 204:1249–1256.
10.
HeurichM, Martínez-BarricarteR, FrancisNJ, et al.Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci U S A, 2011; 108:8761–8766.
11.
GoldB, MerriamJE, ZernantJ, et al.Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet, 2006; 38:458–462.
12.
KavanaghD, YuY, SchrammEC, et al.Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet, 2015; 24:3861–3870.
13.
HallamTM, MarchbankKJ, HarrisCL, et al.Rare genetic variants in complement factor I lead to low FI plasma levels resulting in increased risk of age-related macular degeneration. Invest Ophthalmol Vis Sci, 2020; 61:18.
14.
MastellosDC, RicklinD, LambrisJD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov, 2019; 18:707–729.
15.
LachmannPJ. The story of complement factor I. Immunobiology 2019.
16.
LachmannPJ, HalbwachsL. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol, 1975; 21:109–114.
17.
LayE, NutlandS, SmithJE, et al.Complotype affects the extent of down-regulation by Factor I of the C3b feedback cyclein vitro: in-vitroeffects of complotype. Clin Exp Immunol, 2015; 181:314–322.
18.
LachmannPJ, LayE, SeillyDJ, et al.Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotype. Clin Exp Immunol, 2016; 183:150–156.
19.
NathwaniAC, TuddenhamEG, RangarajanS, et al.Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med, 2011; 365:2357–2365.
20.
RussellS, BennettJ, WellmanJA, et al.Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet, 2017; 390:849–860.
21.
MendellJR, Al-ZaidyS, ShellR, et al.Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med, 2017; 377:1713–1722.
22.
GeorgeLA, RagniMV, Samelson-JonesBJ, et al.Spk-8011: Preliminary results from a phase 1/2 dose escalation trial of an investigational AAV-mediated gene therapy for hemophilia a. Blood, 2017; 130(Suppl 1):604.
23.
NathwaniAC, ReissUM, TuddenhamEGD, et al.long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med, 2014; 371:1994–2004.
24.
CunninghamSC, DaneAP, SpinoulasA, et al.Gene delivery to the juvenile mouse liver using AAV2/8 vectors. Mol Ther, 2008; 16:1081–1088.
25.
XiaoX, LiJ, SamulskiRJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol, 1998; 72:2224–2232.
26.
DaneAP, WowroSJ, CunninghamSC, et al.Comparison of gene transfer to the murine liver following intraperitoneal and intraportal delivery of hepatotropic AAV pseudo-serotypes. Gene Ther, 2013; 20:460–464.
27.
MacanovicM, SinicropiD, ShakS, et al.The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol, 1996; 106:243–252.
28.
MandersonAP, CarlucciF, LachmannPJ, et al.The in vivo expression of actin/salt-resistant hyperactive DNase I inhibits the development of anti-ssDNA and anti-histone autoantibodies in a murine model of systemic lupus erythematosus. Arthritis Res Ther, 2006; 8:R68.
29.
JablonskiP, HowdenBO, RaeDA, et al.An experimental model for assessment of renal recovery from warm ischemia. Transplantation, 1983; 35:198–204.
PerezL. Acute phase protein response to viral infection and vaccination. Arch Biochem Biophys, 2019; 671:196–202.
32.
KoskimiesS, LokkiML, HöckerstedtK. Changes in plasma complement C4 and factor B allotypes after liver transplantation. Complement Inflamm, 1991; 8:257–260.
33.
RichardML, GilkesonG. Mouse models of lupus: what they tell us and what they don't. Lupus Sci Med, 2018; 5:e000199.
34.
BreousE, SomanathanS, BellP, et al.Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology, 2011; 141:348–357, 357.e1–357.e3.
35.
GrossmanTR, HettrickLA, JohnsonRB, et al.Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice. Immunobiology, 2016; 221:701–708.
36.
SekineH, RuizP, GilkesonGS, et al.The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol, 2011; 49:317–323.
37.
LorenzG, AndersHJ. Neutrophils, dendritic cells, toll-like receptors, and interferon-α in lupus nephritis. Semin Nephrol, 2015; 35:410–426.
38.
SekineH, ReillyCM, MolanoID, et al.Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol, 2001; 166:6444–6451.
39.
LisowskiL, DaneAP, ChuK, et al.Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature, 2014; 506:382–386.
40.
PaulkNK, PekrunK, ZhuE, et al.Bioengineered AAV capsids with combined high human liver transduction in vivo and unique humoral seroreactivity. Mol Ther, 2018; 26:289–303.
41.
Cabanes-CreusM, WesthausA, NavarroRG, et al.Attenuation of heparan sulfate proteoglycan binding enhances in vivo transduction of human primary hepatocytes with AAV2. Mol Ther Methods Clin Dev, 2020; 17:1139–1154.
42.
CaoO, DobrzynskiE, WangL, et al.Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood, 2007; 110:1132–1140.
43.
NydeggerUE, FearonDT, AustenKF. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol, 1978; 120:1404–1408.
44.
DreismannAK, McclementsME, BarnardAR, et al.Functional expression of complement factor I following AAV-mediated gene delivery in the retina of mice and human cells. Gene Ther, 2021; 28:265–276.
45.
RoseKL, Paixao-CavalcanteD, FishJ, et al.Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest, 2008; 118:608–618.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
